Becotatug Vedotin in relapsed SCLC: a single-center examine-what-works

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, single-arm exploratory study of becotatug vedotin given IV every 21 days at 2.3 mg/kg in adults with extensive-stage relapsed SCLC. The primary goal is to see if the treatment improves overall survival, with secondary goals including progression-free survival, objective response rate, and safety. Eligible participants have confirmed ES-SCLC, measurable disease, good performance status, and adequate organ function, and must meet contraception requirements. The study is sponsored by Shanghai Pulmonary Hospital in Shanghai, China, with no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed informed consent form (ICF);
2. Age ≥18 years at the time of signing informed consent;
3. Histologically confirmed small cell lung cancer (SCLC);
4. Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment;
5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator;
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
7. Adequate organ and bone marrow function.
8. Women of childbearing potential must use highly effective contraception from screening until 3 months after discontinuation of study treatment and must have a negative pregnancy test (serum or urine) within 7 days before enrollment. Male participants must agree to use appropriate contraception from screening until 3 months after discontinuation of study treatment or have undergone surgical sterilization;
9. No anticancer therapy was received within the specified washout period before the first dose of study treatment;
10. Estimated life expectancy ≥12 weeks.

Exclusion Criteria:

1. Known hypersensitivity to becotatug vedotin;
2. History of another active malignancy requiring treatment or history of allogeneic organ transplantation;
3. Major surgery (excluding diagnostic biopsy) within 4 weeks before the first dose of study treatment;
4. History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection;
5. Active autoimmune disease or history of autoimmune disease with potential risk of recurrence;
6. Current systemic corticosteroid therapy (e.g., prednisone equivalent \>10 mg/day) or use of any other immunosuppressive therapy within 14 days before the first dose of study treatment;
7. Interstitial lung disease (ILD), or previous ILD requiring corticosteroid treatment;
8. History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (including bronchiolitis obliterans organizing pneumonia), or idiopathic pneumonia;
9. Receipt of live vaccines within 28 days before the first dose of study treatment;
10. Any disease or condition that may contraindicate anticancer therapy, including but not limited to active infection, myocardial infarction within 6 months, symptomatic cardiac disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmia), or ongoing immunosuppressive therapy;
11. Pregnancy or breastfeeding; or male or female participants unwilling to use appropriate contraception when pregnancy is possible;
12. Evidence of hereditary bleeding disorders or coagulation abnormalities;
13. History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of \>3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ;
14. Any other medical history, disease, treatment, or laboratory abnormality that may interfere with study results, prevent full participation in the study, or make the participant unsuitable for enrollment as judged by the investigator.

Where it's running

• Shanghai Pulmonary Hospital
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Peng Zhang — Shanghai Pulmonary Hospital, Shanghai, China
• Study coordinator: Peng Zhang
• Email: zhangpeng1121@tongji.edu.cn
• Phone: 02165115006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant PD-L1/VEGF Bispecific Antibody with Chemo versus Chemo plus PD-1 Monoclonal Antibody in Locally Advanced NSCLC

  In people with locally advanced NSCLC, this study tests whether adding a PD-L1/VEGF bispecific antibody to chemotherapy before surgery improves outcomes compared with a PD-1 antibody added to chemotherapy.

  Recruiting at 2 sites Phase 3 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, China and 4 other locations · NCT07863999

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

  This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07820254

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Oliceridine vs Sufentanil for cough during anesthesia induction

  This trial tests whether oliceridine is better than sufentanil at reducing cough during anesthesia induction in adults undergoing elective surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Tianmen, Hubei · NCT07660380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.